BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li C, Li ZC, Ma L, Li LQ, Zhong JH, Xiang BD, Gong WF. Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:749-56. [PMID: 32552297 DOI: 10.1080/17474124.2020.1784727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang X, Chen Y, Xu M, Cheng K, Duan X, Liao W, Wang Y, Lu Y, Duan Z, Wang L. Virologic response maintenance and hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir. Expert Rev Gastroenterol Hepatol 2021;:1-8. [PMID: 34511012 DOI: 10.1080/17474124.2021.1980385] [Reference Citation Analysis]
2 Liu L, Xie S, Teng Y, Deng Z, Chen K, Liu H, Huo R, Liang X, Guo P, Yang D, Ma L, Xiang B, Li L, Zhong J. Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC. Front Oncol 2022;11:783339. [DOI: 10.3389/fonc.2021.783339] [Reference Citation Analysis]
3 Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV. Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology 2021. [PMID: 34918361 DOI: 10.1002/hep.32241] [Reference Citation Analysis]
4 Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Reference Citation Analysis]